论文部分内容阅读
作者对慢性丙型肝炎患者在α-干扰素(IFN-α)治疗前、治疗中和治疗后血清HCV核心蛋白检测的临床应用价值进行评价。 27例用IFN-α治疗的慢性丙型肝炎患者,男19例,女8例,年龄32～65(平均50.6)岁,均有血清抗-HCV和HCV RNA,且HBsAg和抗-HIV阴性。重组IFN-α2a以9MU剂量每天肌注1次共2周,继以每周3次共22周。开始治疗后对患者进行观察,并至少至治疗完成后24周。若(1)血清ALT浓度在治疗中恢复正常并在完成治疗后保持
The authors evaluate the clinical value of serum HCV core protein detection in patients with chronic hepatitis C before, during and after interferon-alpha (IFN-α) treatment. Twenty-seven patients with chronic hepatitis C treated with IFN-α, 19 males and 8 females, aged 32-65 years (mean, 50.6 years), had serum anti-HCV and HCV RNA and had negative HBsAg and anti-HIV. Recombinant IFN-α2a was administered intramuscularly once a day for 2 weeks at a dose of 9 MU followed by 3 times a week for a total of 22 weeks. The patient is observed after starting treatment and is at least 24 weeks after the treatment is completed. If (1) serum ALT levels returned to normal during treatment and were maintained after treatment was completed